Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04539886
Other study ID # NP-SC-012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 28, 2020
Est. completion date November 18, 2021

Study information

Verified date April 2024
Source Pulse Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed as a multi-center, single-blinded, prospective, randomized, study to compare the safety and effectiveness of the CellFX System to the comparator group, Electrodessication for the treatment of SH lesions in healthy adult subjects.


Description:

This SH comparative study will evaluate safety and efficacy in a split face design using the CellFX System and pre-defined energy profile for all primary and secondary treatments based on Fitzpatrick Skin Types and tip size. The comparator group will be treated with the same standardized intralesional electrodesiccation procedure conducted by all participating clinical sites. Subjects with 4-10 qualifying SH lesions on the face except the scalp, nose and within the orbital region will be enrolled. Each subject will be evaluated by the blinded site investigator at 7-days, 30-days, and 60-days post-initial CellFX and Electrodessication treatments. At the 30-day follow-up visit, lesions will be evaluate using Global Aesthetic Improvement Scale (GAIS), for eligibility to receive an additional treatment. In case of a second treatment, the subject will be evaluated by the blinded site investigator at 30-days and 60-days post-retreatment. Photography of the study lesions will be captured along with the blinded site investigator assessments at all visits.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date November 18, 2021
Est. primary completion date February 2, 2021
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: - Subject is at least 21 and no older than 80 years of age. - Subject gives voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained. - Subject must comply with study procedures including follow-up visits. - Subject is willing to have SH lesions treated in a single treatment session and understands that their lesion(s) may undergo a second treatment session at a subsequent visit. - Subject must have a minimum of four SH lesions and up to 10 SH lesions to be treated and the subject must have at least two SH lesions located on each side of the face. - For study purposes, the SH lesions must be no greater than 2 mm in height and must not exceed 5 mm x 5 mm at their largest dimension. The subject's lesions cannot be located within the eye orbit, nose, or scalp. - Subject consents to have photographs taken of the SH lesion(s). - Subject agrees to refrain from using all other lesion removal products or treatments (e.g. retinols, retinoids, and exfoliating products) to the treated SH lesions or any new SH lesions during the study period. - Subject agrees to refrain from prolonged sun exposure during the study period. Exclusion Criteria: - Subject has an implantable electronic medical device.(i.e., pacemaker, implantable cardioverter defibrillator) - Subject has an active infection or history of infection in designated test area within 90 days prior to first treatment. - Subject is not willing or able to sign the Informed Consent. - Subject is known to be immune compromised. - Subject is prone to developing hypertrophic scars or to be a keloid producer. - Subject has allergies to Lidocaine or Lidocaine-like products. - Subject is employed by the sponsor, clinic site, or entity associated with the conduct of the study. - Have any condition or situation which, in the Investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study. - Use of any other investigational drug, therapy, or device within the past 30 days of enrollment or concurrent participation in another research study. - Subject was previously treated with CellFX for SH lesions.

Study Design


Intervention

Device:
CellFX System
CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
Intralesional Electrodesiccation
Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode

Locations

Country Name City State
United States Dermatology, Laser & Vein Specialists of the Carolinas, PLLC Charlotte North Carolina
United States Zel Skin & Laser Specialists Edina Minnesota
United States Austin Institute for Clinical Research, Inc. Houston Texas
United States Austin Institute for Clinical Research, Inc. Pflugerville Texas
United States Investigate MD, LLC Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Pulse Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Lesions With Improvement as Assessed With the Global Aesthetic Improvement Scale (GAIS) Percentage of SH Lesions with Improvement as Assessed by Blinded Investigator During Live Assessments based on Global Aesthetic Improvement Scale (GAIS). The Global Aesthetic Improvement Scale ranges from 1=Very Much Improved or Excellent Corrective Result to 5=Worsened Appearance Compared with Original Condition. The primary effectiveness endpoint of improvement at 60-days post-last treatment as assessed "live" by the blinded site investigator using the 5-point GAIS 60 days post last CellFX or Electrodessication treatment, up to a maximum of 3 months.
Primary Percentage of Lesions With Hyperpigmentation, Hypopigmentation and Scarring as Assessed by Blinded Investigator During Live Assessments The first co-primary safety endpoint includes the percentage of lesions showing hyperpigmentation and scarring as assessed by the blinded Investigator at 60 days after the last treatment with CellFX or Electrodessication 60 days post last CellFX or Electrodessication treatment, up to a maximum of 3 months.
Primary Percentage of Lesions With Skin Textual Changes as Assessed by Blinded Investigator During Live Skin Assessment The second co-primary safety endpoint of skin textural changes including; flaking, erythema, crusting, scabbing, or other skin irregularities was assessed by the blinded site investigator at 30 days post last CellFX or Electrodessication treatment. 30 days post last CellFX or Electrodessication treatment, up to a maximum of 2 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05418959 - Genetic Risk Stratification of Pediatric Skin Lesions Phase 1
Recruiting NCT05068310 - Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
Completed NCT05619471 - VIO Imaging for Skin Tissue Assessment (VISTA) N/A
Recruiting NCT03716193 - Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry N/A
Completed NCT03914274 - Adequate Sock to Avoid Hiking Injuries N/A
Completed NCT04821193 - Comparison of the Effects of 5%NaHCO3, 2%CHG and 70%Alcohol in the Prevention of Infections Related to Catheter N/A
Completed NCT05729334 - Clinical Investigation EUCLIDES-01 for the Calculation of the Area of Skin Lesions N/A
Completed NCT02598609 - SEPREVEN: a Stepped-wedge Randomised Controlled Trial N/A
Completed NCT05994781 - A Prospective Researcher-led Clinical Study of Neopep-S-based EasyDew MD Regen Cream N/A
Completed NCT06025058 - Neopep-S-based EasyDew MD Regen Cream for Radiotherapy Subject After Breast Tumor Resection N/A
Completed NCT00470912 - Sunscreen RV 2457C in Photoinduced CLE Phase 3
Completed NCT05410964 - Non-Linear Imaging of Skin In Vivo
Withdrawn NCT03357419 - The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions N/A
Completed NCT02740257 - Smartphone Application to Detect Skin Lesions
Completed NCT03612570 - Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia N/A
Recruiting NCT03796871 - Medical Device Based on Polarized Light for Cutaneous Lesions Visualization N/A
Completed NCT05238870 - Prevention of Skin Damage in the Patient in Prone Position: Development of Education Interventions Based on a Training Needs Assessment Study.
Completed NCT05940090 - Correlation of Dermatologist Made Biopsy Decision With AI Assisted Total Body Photography Detection of Outlier Lesions
Enrolling by invitation NCT04566302 - Pilot Study of Imaging Human Skin With High-Speed Spectrally Encoded Confocal Microscopy N/A
Completed NCT04470466 - Short Pulse and Q-switched ND-YAG Laser With Topical Carbon Versus Fractional CO2 Laser for Enlarged Facial Pores N/A